POINT Biopharma Global Inc.

POINT Biopharma Global Inc. (Nasdaq: PNT) is a radiopharmaceutical company that entered public markets in 2021 through a business combination with GX Acquisition Corp. II, a blank-check vehicle sponsored by The Gores Group. The company was focused on the development and commercial-scale manufacturing of radioligand therapies for oncology. An 8-K filed December 27, 2023 corresponds to the closing of Eli Lilly and Company's acquisition of POINT Biopharma, a transaction Lilly announced in October 2023, effectively ending PNT's tenure as a publicly traded entity. For full filing history, sponsor-level data, and transaction analytics on PNT and thousands of other SPAC deals, sign up for SpacDesk.